Ascendis Pharma A/S
ASND
$209.05
$8.554.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -255.99M | -293.74M | -367.37M | -410.04M | -462.57M |
| Total Depreciation and Amortization | 18.64M | 18.75M | 18.59M | 18.66M | 19.23M |
| Total Amortization of Deferred Charges | 497.80K | 497.80K | 497.80K | 497.80K | 520.00K |
| Total Other Non-Cash Items | 212.94M | 125.29M | 108.60M | 172.79M | 180.52M |
| Change in Net Operating Assets | -89.90M | -28.83M | 4.00M | -112.81M | -21.39M |
| Cash from Operations | -113.80M | -178.03M | -235.69M | -330.90M | -283.70M |
| Capital Expenditure | -6.17M | -6.66M | -2.11M | -1.58M | -1.07M |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 1.02M | 1.02M | 1.03M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.30K | 37.30K | 37.30K | 8.02M | 15.07M |
| Cash from Investing | -6.13M | -6.63M | -1.05M | 7.46M | 15.03M |
| Total Debt Issued | 0.00 | 134.16M | 134.16M | 134.16M | 130.63M |
| Total Debt Repaid | -18.07M | -14.31M | -11.65M | -11.37M | -11.15M |
| Issuance of Common Stock | 94.05M | 345.16M | 333.05M | 340.43M | 320.12M |
| Repurchase of Common Stock | -28.79M | -28.79M | -28.79M | -- | -1.81M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -19.29M | -19.29M | -19.29M | -19.29M | -- |
| Cash from Financing | 34.47M | 459.44M | 448.88M | 487.84M | 481.23M |
| Foreign Exchange rate Adjustments | -3.09M | -12.74M | 10.77M | 24.22M | -6.48M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -88.56M | 262.05M | 222.91M | 188.63M | 206.09M |